List of Excipients in Branded Drug IMJUDO

IMJUDO Excipient Strategy and Commercial Opportunities: Formulation, Manufacturing, and Patent Analysis

Last updated: August 9, 2026

IMJUDO is AstraZeneca’s intravenous tremelimumab-actl, a monoclonal antibody used with durvalumab for selected solid tumors. Its commercial opportunity is concentrated in formulation supply, aseptic manufacturing, biosimilar development, analytical comparability, and combination-product logistics rather than in conventional small-molecule generic substitution. The marketed formulation uses a relatively limited excipient system: histidine buffer, trehalose, disodium edetate, polysorbate 80, and water for injection.[1]

What is IMJUDO and how is it administered?

IMJUDO contains tremelimumab-actl, a fully human IgG2 monoclonal antibody targeting CTLA-4. The U.S. product is supplied as a 20 mg/mL concentrate in a single-dose vial for intravenous infusion after dilution.[1]

Attribute	IMJUDO commercial profile
Active ingredient	Tremelimumab-actl
Drug class	Anti-CTLA-4 monoclonal antibody
Manufacturer	AstraZeneca
Dosage form	Intravenous infusion concentrate
Strength	20 mg/mL
Container	Single-dose vial
Primary combination partner	Durvalumab, marketed as IMFINZI
Key indication	Unresectable hepatocellular carcinoma in combination with durvalumab
FDA approval	October 2022 for the HCC regimen
Administration	Dilution in an appropriate intravenous solution followed by infusion
Regulatory category	Biologic, not a conventional small-molecule drug

The product’s intravenous route limits opportunities for oral delivery, transdermal delivery, or consumer-facing reformulation. The higher-value opportunities involve improving stability, reducing protein loss, increasing manufacturing throughput, and creating biosimilar-ready formulations.

What excipients are used in IMJUDO?

The IMJUDO formulation contains excipients selected to control pH, maintain protein stability, limit metal-catalyzed degradation, reduce aggregation, and support vial presentation.[1]

Excipient	Likely formulation role	Commercial relevance
Histidine	Primary buffering agent	Requires control of pH, concentration, and raw-material quality
Histidine hydrochloride monohydrate	Complements histidine buffer system	Supports pH control and ionic balance
Trehalose dihydrate	Nonreducing sugar and stabilizer	Protects protein structure during storage and stress exposure
Disodium edetate	Chelating agent	Binds trace metals that can promote oxidation or degradation
Polysorbate 80	Surfactant	Reduces interfacial stress, adsorption, and agitation-related aggregation
Water for injection	Diluent	Must meet parenteral water and bioburden requirements

The combination is commercially important because monoclonal antibodies can lose potency through aggregation, oxidation, deamidation, fragmentation, surface adsorption, and particulate formation. Each excipient affects the product’s critical quality attributes and the control strategy required for release and stability testing.

Why does polysorbate 80 matter for IMJUDO manufacturing?

Polysorbate 80 is often the most operationally sensitive excipient in antibody formulations. It can degrade through hydrolysis and oxidation, producing free fatty acids, subvisible particles, and other species that may affect product quality.[2]

For IMJUDO-like formulations, manufacturers must control:

• Polysorbate concentration at release and throughout shelf life.
• Peroxide and carbonyl impurities.
• Interaction with container closures and tubing.
• Agitation during shipping and compounding.
• Formation of particles after dilution.
• Lot-to-lot variability in excipient purity.

This creates opportunities for high-purity polysorbate suppliers, excipient testing laboratories, oxidation-control technologies, and analytical platforms capable of measuring low concentrations in protein matrices.

What is the role of trehalose and EDTA?

Trehalose helps stabilize the antibody by supporting the native protein structure during temperature excursions and other physical stresses. It may reduce aggregation and conformational change, although its performance depends on the complete formulation and the antibody molecule.

Disodium edetate is present at low concentration but can have a disproportionate quality-control role. Trace metals can accelerate oxidation and other degradation pathways. EDTA reduces that risk by chelating metal ions. Suppliers and biosimilar developers must control identity, purity, elemental impurities, and compatibility with the container system.

What formulation opportunities exist for IMJUDO?

The most credible opportunities are improvements that preserve the clinical route while reducing manufacturing and administration costs.

High-value formulation opportunities

1. Lower-concentration or higher-concentration presentations.
   A higher concentration could reduce infusion volume and improve shipping efficiency. A lower concentration could improve manufacturability or reduce viscosity if the current antibody concentration creates processing constraints.

2. Ready-to-use diluted infusion bags.
   A pharmacy-ready presentation could reduce compounding labor and preparation errors. The product would require validated in-use stability, container compatibility, particulate control, and extractables and leachables data.

3. Reduced-volume combination regimens.
   IMJUDO is commonly used with durvalumab. Coordinated presentations could simplify preparation of the regimen, although separate biologic stability and compatibility requirements would apply.

4. Improved surfactant systems.
   Alternative surfactants, including polysorbate 20 or poloxamer-based systems, could be evaluated if they improve oxidation resistance or particle control. A formulation change would require substantial comparability data because surfactant identity can affect aggregate levels, immunogenicity risk, and stability.

5. Subcutaneous delivery.
   Subcutaneous administration could expand outpatient use, but it would require a substantially higher concentration, injection-volume control, local tolerability testing, device development, and clinical bridging. This is a longer-term opportunity rather than a near-term excipient substitution.

6. More robust cold-chain performance.
   A formulation that tolerates brief temperature excursions could lower distribution costs and reduce product loss. Such a claim would require formal stability studies under defined conditions.

What patents protect IMJUDO excipients and formulations?

IMJUDO’s protection is likely divided among biologic composition, antibody sequence, therapeutic use, manufacturing, formulation, and regulatory exclusivity. The FDA label alone does not establish the full patent estate or patent expiration dates.[1]

Because IMJUDO is a biologic, it is not listed in the Orange Book in the same manner as a conventional small-molecule product. Relevant patent and exclusivity analysis should focus on:

• U.S. patents assigned to AstraZeneca or related entities.
• Patent Cooperation Treaty filings covering tremelimumab sequences.
• Continuation and divisional applications.
• Formulation claims covering histidine, trehalose, EDTA, and surfactant combinations.
• Method-of-use claims for HCC and other cancer regimens.
• Manufacturing claims covering cell culture, purification, and antibody processing.
• Purple Book reference-product and exclusivity status.
• FDA-approved labeling and biologic license records.

Excipient patents are unlikely to provide a complete barrier on their own because histidine, trehalose, EDTA, polysorbate 80, and water for injection are established pharmaceutical materials. The stronger protection generally comes from the antibody molecule, specific formulation parameters, therapeutic combinations, and manufacturing processes.

When does IMJUDO lose exclusivity?

The statutory U.S. biologic exclusivity period is generally 12 years from first licensure, with a four-year period during which a biosimilar application cannot be submitted.[3] Based on the October 2022 approval date, the reference product’s principal statutory biologic exclusivity period would generally extend into October 2034, subject to the legally operative first-licensure date and any applicable statutory calculation.[4]

Patent protection may extend beyond or expire before regulatory exclusivity. Patent expiration dates cannot be inferred from the approval date. A commercial launch assessment must separate:

Protection layer	Relevance to IMJUDO
FDA biologic exclusivity	Delays biosimilar approval and application timing
Composition-of-matter patents	Can protect tremelimumab sequence or antibody structure
Formulation patents	May cover excipient ratios, concentration, pH, or stability
Method-of-use patents	May cover cancer indications or treatment regimens
Manufacturing patents	May cover cell lines, purification, or process conditions
Orphan-drug exclusivity	May apply only if the approved indication qualifies and statutory requirements are met
Pediatric exclusivity	Could add six months if granted under applicable conditions

What is the Orange Book and Purple Book status of IMJUDO?

IMJUDO is a biologic and should be evaluated through the FDA’s Purple Book framework rather than conventional Orange Book patent-certification procedures.[4] A biosimilar applicant would use the Biologics Price Competition and Innovation Act pathway, not an abbreviated new drug application with a Paragraph IV certification.[3]

Are Paragraph IV challenges available for IMJUDO?

A traditional Paragraph IV challenge is not the primary route for IMJUDO because Paragraph IV certifications apply to listed patents associated with small-molecule drug applications. Biosimilar developers instead may challenge patents through the BPCIA patent-information exchange, declaratory judgment actions, inter partes review, post-grant review, or other patent litigation mechanisms.

The commercial effect is similar: a biosimilar developer can contest composition, formulation, use, or manufacturing patents before launch. The legal process and timing differ from an ANDA case.

What generic or biosimilar entry risks exist for IMJUDO?

IMJUDO faces biosimilar risk rather than conventional generic risk. The main barriers are:

• High cost of comparative analytical development.
• Need to establish similarity across structure, purity, potency, and functional activity.
• Limited clinical interchangeability between tremelimumab and durvalumab regimens.
• Complex manufacturing and aseptic filling requirements.
• Control of aggregates, particles, oxidation, and surfactant degradation.
• Patent claims covering sequence, formulation, use, or production.
• Physician and payer concerns about substitution in oncology combinations.

A first biosimilar would likely compete on net price, supply reliability, vial configuration, contracting terms, and health-system integration. An interchangeable designation, if pursued and granted, could increase substitution potential, but oncology biologics are often selected through institutional protocols and payer arrangements rather than pharmacy-level automatic substitution.

Which companies could challenge AstraZeneca commercially?

The most credible challengers are established oncology-biologics manufacturers with:

• Existing monoclonal antibody cell-culture capacity.
• Experience with CTLA-4 or checkpoint inhibitors.
• Commercial oncology sales infrastructure.
• Biosimilar regulatory capabilities.
• Access to high-quality polysorbate, trehalose, and parenteral excipient supply.
• Ability to manufacture both the antibody and compatible combination products.

Potential competition is more likely to come from global biosimilar companies and large contract development and manufacturing organizations than from excipient companies alone. Excipient suppliers can capture value without owning a competing biologic by supplying qualified materials, stability-indicating assays, and formulation-development services.

What commercial opportunities exist in IMJUDO excipients?

The opportunity is distributed across the supply chain.

Excipient supply

High-purity polysorbate 80 is the most commercially differentiated component. Suppliers can compete on low peroxide levels, oxidation control, batch consistency, regulatory documentation, and supply continuity. Trehalose suppliers can compete on parenteral grade, endotoxin control, and trace-metal specifications.

Analytical services

Demand exists for:

• Polysorbate quantification.
• Peroxide and degradation-product testing.
• Aggregate and subvisible-particle analysis.
• Oxidation and deamidation mapping.
• Host-cell protein and residual DNA testing.
• Container-closure integrity testing.
• Extractables and leachables studies.
• Stability-indicating methods for diluted infusion solutions.

Contract manufacturing

Aseptic fill-finish providers can offer value through single-dose vial filling, low-volume biologic handling, cold-chain logistics, and combination-regimen packaging. Ready-to-use infusion presentations would expand the addressable manufacturing opportunity but require greater validation and distribution controls.

Formulation licensing

AstraZeneca or a biosimilar developer could license platform technologies that improve surfactant stability, reduce aggregation, or enable higher-concentration delivery. The strongest licensing candidates would have data in monoclonal antibodies rather than excipient concepts alone.

How strong is the IMJUDO excipient strategy?

The marketed excipient system is conventional, rational, and compatible with established parenteral manufacturing. Its strength comes from the complete formulation and manufacturing process, not from any individual excipient.

Factor	Assessment
Ingredient availability	High
Formulation complexity	Moderate
Surfactant sensitivity	Material
Biosimilar replication difficulty	Moderate to high
Excipient patent barrier	Likely limited
Manufacturing barrier	High
Analytical burden	High
Subcutaneous reformulation opportunity	Technically possible but development-intensive
Ready-to-use presentation opportunity	Commercially attractive but validation-intensive

The practical moat is therefore strongest in antibody production, process control, analytical comparability, clinical evidence, and regulatory execution.

What patent litigation affects IMJUDO?

Publicly available regulatory materials establish IMJUDO’s biologic status and labeling but do not, by themselves, provide a complete litigation history or definitive patent-expiration schedule.[1][4] Future disputes are most likely to involve:

• Tremelimumab antibody sequence or structural claims.
• Combination use with durvalumab.
• HCC or other oncology treatment methods.
• Formulation concentration and excipient combinations.
• Cell-culture or purification processes.
• Biosimilar manufacturing and patent-disclosure obligations.

Settlement agreements could delay biosimilar launch while permitting entry before the end of all asserted patent terms. Any settlement analysis must distinguish regulatory exclusivity from patent-based launch restrictions.

What geographic opportunities exist?

The United States offers the highest-value biologic exclusivity and patent-litigation market. Europe and Japan provide separate biosimilar pathways and pricing dynamics. Emerging markets may offer earlier commercial access but lower net prices and more variable enforcement.

Excipient and manufacturing companies can pursue geographic opportunities through:

• European Medicines Agency biosimilar development.
• U.S. FDA 351(k) programs.
• Regional fill-finish partnerships.
• Localized cold-chain distribution.
• Supply agreements for polysorbate 80 and trehalose.
• Technology transfer for aseptic vial filling.

Key Takeaways

• IMJUDO is a 20 mg/mL intravenous tremelimumab formulation supplied in a single-dose vial.
• Its principal excipients are histidine, histidine hydrochloride monohydrate, trehalose dihydrate, disodium edetate, polysorbate 80, and water for injection.
• Polysorbate 80 quality and degradation control are the most differentiated excipient opportunities.
• The product is governed by biologic and Purple Book principles, not conventional Orange Book Paragraph IV procedures.
• U.S. biologic exclusivity would generally extend into 2034 based on the 2022 first approval, subject to statutory calculation.
• Commercial barriers are stronger in antibody manufacturing, analytical comparability, clinical use, and regulatory execution than in commodity excipient access.
• The most attractive opportunities are high-purity excipient supply, analytical testing, aseptic fill-finish, ready-to-use presentations, and biosimilar formulation platforms.

FAQs

Can IMJUDO be reformulated as a prefilled syringe?

A prefilled syringe is technically possible but would require concentration, viscosity, device compatibility, silicone-oil, extractables, particulate, and stability studies. The current vial presentation is better aligned with hospital infusion workflows.

Could polysorbate 80 be replaced in an IMJUDO biosimilar?

Yes, but replacement would increase comparability risk. A biosimilar developer would need to demonstrate that the alternative surfactant does not alter aggregation, potency, immunogenicity-related quality attributes, or shelf life.

Does IMJUDO need a new excipient for subcutaneous delivery?

Not necessarily, but subcutaneous delivery would probably require a substantially revised formulation. Higher concentration, injection volume, local tolerability, viscosity, and device performance would become central development constraints.

Can an excipient supplier obtain blocking patent protection around IMJUDO?

A supplier could seek patents on specific stabilized formulations, impurity-controlled excipient compositions, or manufacturing methods. Broad ownership of common excipients such as trehalose or polysorbate 80 would be difficult to establish.

Is IMJUDO more exposed to biosimilar competition than durvalumab?

The answer depends on patent scope, indication breadth, clinical uptake, and combination-regimen economics. IMJUDO’s smaller commercial base may reduce the incentive for early biosimilar investment, while its use with durvalumab creates an integrated treatment regimen that can raise development and contracting complexity.

References

1. U.S. Food and Drug Administration. (2024). IMJUDO (tremelimumab-actl) injection, for intravenous use: Prescribing information. AstraZeneca Pharmaceuticals LP.

2. Kerwin, B. A. (2008). Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. Journal of Pharmaceutical Sciences, 97(8), 2924-2935.

3. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.

4. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. FDA.